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Abstract Oxidative stress leads to lipid peroxidation and
may contribute to the pathogenesis of lesions in multiple
sclerosis (MS), an autoimmune disease characterized by
inﬂammatory as well as degenerative phenomena. Iso-
prostanes are prostaglandin-like compounds which are
formed by free radical catalysed peroxidation of arachi-
donic acid esteriﬁed in membrane phospholipids. They are
a new class of sensitive speciﬁc markers for in vivo lipid
peroxidation. In this study 26 patients (15 females and 11
males; mean age 48.2 ± 15.2 year; mean disease duration
10.0 ± 6.5 year) with secondary progressive MS (SPMS)
and 12 healthy controls were enrolled. In patients with
multiple sclerosis the lipid peroxidation as the level of
urine isoprostanes and the level of thiobarbituric acid
reactive species (TBARS) in plasma were estimated.
Moreover, we estimated the total antioxidative status
(TAS) in plasma. It was found that the urine isoprostanes
level was over 6-fold elevated in patients with SPMS than
in control (P\0.001). In SPMS patients TBARS level
was also statistically higher than in controls (P\0.01).
However, we did not observed any difference of TAS level
in serum between SPMS patients and controls (P[0.05).
In patients with SPMS the lipid peroxidation and oxidative
stress measured as the increased level of isoprostanes was
observed. Thus, we suggest that the level of isoprostanes
may be used as non-invasive marker for a determination of
oxidative stress what in turn, together with clinical symp-
toms, may determine an speciﬁc antioxidative therapy in
SPMS patients.
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Introduction
Multiple sclerosis (MS) is a complex disease with several
pathophysiological processes: inﬂammation, demyelina-
tion, oxidative stress, axonal damage and repair mecha-
nisms that participate in this disorder. These processes are
not uniformly represented in patient populations but can
selectively predominate in individual patients. Therefore,
heterogeneity in phenotypic expression of MS has the
effects on the prognosis and response to therapies in MS
patients. In MS disease with a complex pathogenesis iso-
prostanes as a biomarker of lipid peroxidation reﬂect only
one of many ongoing pathogenic processes i.e. oxidative
stress. There is a need for developing new therapies espe-
cially in progressive phase of MS that are more process-
speciﬁc and can be used in speciﬁc patient subpopulations
[1]. There are three main types of MS, deﬁned as: relaps-
ing-remitting (RR), secondary progressive (SP) and pri-
mary-progressive (PP) with progressive-relapsing (PR)
recently distinguished as an additional subtype [2]. SPMS
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augmented symptoms.
There is evidence that MS is not only characterized by
immune mediated inﬂammatory reactions but also by
neurodegenerative processes. Accumulating data indicate
that oxidative stress (OS) plays an important role in this
process [3–5]. Oxidative stress leads to lipid peroxidation
and may contribute to the pathogenesis of lesions in mul-
tiple sclerosis. Polysaturated fatty acids (PUFA) are major
components of neuron membranes, which are highly sus-
ceptible to reactive oxygen species (ROS) attack and are
the source of lipid peroxidation products. The deregulated
metabolism of lipids may be of particular importance for
central nervous system (CNS) disorders, as this organ has
the highest lipid concentration next to adipose tissue [6].
The brain is believed to be particularly vulnerable to
oxidative stress as it contains high concentrations of PUFA
that are susceptible to lipid peroxidation, consumes rela-
tively large amounts of oxygen for energy production and
has lower antioxidant defenses compared to other organs
[7, 8]. Of all the brain cells, neurons are particularly vul-
nerable to oxidative insults due to low levels of reduced
glutathione [9]. Peroxidation of lipids can disrupt the
organization of the membrane, causing changes in ﬂuidity
and permeability, inhibition of metabolic processes and
alterations of ion transport. Damage to mitochondria
induced by lipid peroxidation can lead to further ROS
generation. In the presence of oxygen radicals, double
bonds of unsaturated fatty acids of phospholipids are oxi-
dized. A scission of the oxidized polyunsaturated fatty
acids results in formation of phospholipid aldehydes such
as oxidized phosphatidylcholine (OxPC), and aldehyde
cleavage fragments including malonyldialdehyde (MDA),
4-hydroxynonenal (HNE) and acrolein [6].
Free radical catalysed peroxidation of arachidonic acid
esteriﬁed in membrane phospholipids leads to the forma-
tion of isoprostanes which are prostaglandin-like com-
pounds. They are sensitive and speciﬁc markers of in vivo
lipid peroxidation and oxidative tissue injury [10, 11].
The aim of this study was to evaluate lipid peroxidation
as a isoprostanes level in urine and TBARS level in serum
of multiple sclerosis patients with secondary progressive
clinical course. The measurement of the total antioxidant
status (TAS) of SPMS patients was also investigated in our
study.
Experimental Procedure
Patients
Subjects with clinically deﬁnite MS according to McDonald
criteria were included to the study. Secondary progressive
course of MS was ascertained as deﬁned by Lubin et al. [12]
andpatientswereobservedforoneyearbefore.SPMScanbe
recognized when initial relapsing-remitting course is fol-
lowed by progression, with or without occasional relapses,
minor remissions and plateaux.
Twenty-six of MS patients with secondary progressive
disease course (SPMS) and 10 healthy controls (HCs) were
enrolled in our study. The MS group consisted of 15 females
and 11 males, mean age 48.2 ± 15.2 years and mean EDSS
score 6.5 ± 2.0 with a mean disease duration of
10.0 ± 6.5 years (Table 1). The patients were under Neu-
rorehabilitation Ward control for 5 weeks and in that time
they received no immunomodulators, immunostimulators,
hormons, vitamins, minerals or any other substitutions with
antioxidative properties. Prior to the study, all the subjects
had undergone medical check-ups including neurological
and internist examination. All healthy controls were
screened to be free from any neurological or other major
medical illnesses and were matched on age to study group
(no differences were calculated, P[0.05) (Table 1).
The protocol and procedures were done according to
the Helsinki Declaration and were approved by Ethics
Committee of the Medical University of Lodz, Poland. The
study was performed at the Neurorehabilitation Division,
III General Hospital Lodz, Department of Chemistry and
Clinical Biochemistry, Medical University of Lodz, and
Department of General Biochemistry, University of Lodz,
Poland.
Blood Samples Collection
Blood samples from MS patients and healthy controls were
collected into cooled EDTA containing tubes and were
centrifuged to isolate plasma and erythrocytes. Erythro-
cytes were separated from blood plasma by centrifugation
(10 min, 710 g) at 4C and washed 3 times with 0.9%
NaCl before examination.
Estimation of 8-isoPGF2a
The level of urinary isoprostane (8-isoPGF2a) was deter-
minated from SPMS patients and controls using an
Table 1 Characteristics of study subjects
Healthy controls n = 10 SPMS n = 26
Mean age (years) 45.8 ± 12.9 48.2 ± 15.2
Female n (%) 7 (70%) 15 (73.3%)
EDSS* 6.5 ± 2.0
Disease duration (years) 10.0 ± 6.5
EDSS* Expanded disability status scale
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123immunoassay kit Randox according to the manufacturer’s
instruction. 8-isoPGF2a in samples of urine (100 ll) or
standards competes for binding (to the antibody coated on
the plate) with 8-isoPGF2a conjugated to horseradish
peroxidase (HRP). The peroxidase activity results in colour
development in the substrate when added. The intensity
of colour is proportional to the amount of HRP-bound
8-isoPGF2a and inversely proportional to the amount of
8-isoPGF2a in the samples (or standards) [13–15].
Estimation of TBARS
TBARS estimation in plasma. Samples of plasma were
transferred to an aqual volume of 20% (v/v) cold trichlo-
roacetic acid in 0.6 M HCl and centrifuged at 1,2009g for
15 min. One volume of clear supernatant was mixed with
0.2 vol. of 0.12 M thiobarbituric acid in 0.26 M Tris, pH
7.0 and immersed in a boiling water bath for 15 min.
Absorbance at 532 nm was measured and results are
expressed as nmol of TBARS.
Evaluation of the Total Antioxidant Status
The determination of the total antioxidant status in blood
plasma was performed by spectrophotometric method
according to procedure no. NX2332 by Randox (Randox
Laboratories Ltd. Ardmore, Diamond Road, Crumlin, Co
Antrim, United Kingdom, BT29 4QY). The plasma volume
taken to estimation was 5 ll, a total assay volume was
305 ll. Brieﬂy, ABTS (2,20-Azino-di-[3ethylbenzthiazo-
line sulphonate]) was incubated with peroxide (metmyo-
globin) and H2O2 to produce the radical cation ABTS with
a relatively stable blue-green colour. Antioxidants when
added in examined sample caused suppression of this
colour production measured as decrease of absorbance with
a spectrometer (UV/VIS Spectrometer Lambda 14P, Perkin
Elmer, USA) at 600 nm. The total antioxidant status was
calculated as concentration of antioxidants [mmol/l].
Statistical Analysis
The data point in this study was calculated for three sep-
arate experiments from each analyzed patient or control
sample. An enzymes activity as well as total antioxidant
status was expressed as mean value ± SD. Blinded repli-
cate samples were used for quality control (QC). If no
signiﬁcant differences between variations were found, as
assessed by the Snedecor-Fisher test, the differences
between means were evaluated by applying the Student’s
t test. Otherwise, the Cochran-Cox test was used. The data
were analyzed using the STATISTICA (StatSoft, Tulsa,
OK) statistical package.
Results
Lipid peroxidation measured as urine isoprostanes (8-EPI)
was over 6-fold higher in urine of SPMS patients than in
healthy volunteers (Fig. 1). The level of isoprostanes
reached a mean value of 624 ng/ml (SD = 6.78) in urine of
SPMS patients while for healthy controls the level reached
a mean value of 93 ng/ml (SD = 22.11), respectively
(Table 2). TBARS level was also statistically signiﬁcantly
elevated in plasma obtained from SPMS patients
(P\0.01) (Fig. 2; Table 2). However, there were no sta-
tistical signiﬁcant difference of TAS level in plasma of
SPMS patients according to control subjects in our study
(Fig. 3; Table 2).
Discussion
Disability levels in SPMS patients often worsen despite a
stable MRI T(2)(magnetic resonance) lesion burden. The
presence of oxidative stress in the absence of measurable
inﬂammation could help explain this phenomenon [16].
Lipid peroxidation has been implicated in the pathogenesis
of multiple sclerosis (MS). Isoprostanes, isomers of
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Fig. 1 Isoprostanes (8-EPI) in urine of secondary progressive
multiple sclerosis (SPMS) patients and controls
Table 2 Lipid peroxidation measured as urine isoprostanes (8-EPI)
and plasma TBARS as well as total antioxidative status (TAS) in
secondary progressive multiple sclerosis (SPMS) patients
SPMS n = 30 Healthy n = 10
XS D XS D
Isoprostanes(8-EPI) [ng/ml] 624 6.78 93 22.11
TBARS [lM] 0.553 0.145 0.336 0.063
TAS [mM] 0.84 0.089 0.85 0.075
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123prostaglandins, are produced by free radical-mediated
peroxidation of fatty acids in vivo and can be quantiﬁed in
biological ﬂuids. In the present study, we estimated the
level of lipid peroxidation in urine as well as plasma of MS
patients [13–15].
In our study the urine level of the isoprostane 8-epi-
prostaglandin (PG)-F2a which is considered as a reliable
marker of oxidative stress in vivo was over six times higher
in SPMS patients than control subjects. The increased level
of 8-epi-prostaglandin (PG)-F2a in cerebrospinal ﬂuid
(CSF) of MS patients in several studies has been described
[10].
In neurodegenerative diseases, neuronal and axonal loss
is mediated by oxidative stress and excitotoxicity that
constitute a ﬁnal common toxic pathway. Most impor-
tantly, peroxynitrite is a key mediator of those two inter-
twined pathomechanisms. In MS, peroxynitrite consistently
produces highly toxic nitrating and oxidizing radical spe-
cies that may alter mitochondrial structure and function by
a wide range of lesions including lipid, protein and DNA.
During the remitting phase, peroxynitrite participates in
neuron and oligodendrocyte damage associated with
inﬂammatory processes. Moreover, in the chronic phase of
the disease, peroxynitrite contributes to self-perpetuating
mechanisms responsible for its progression [17].
Central nervous system (CNS) is particularly susceptible
to ROS-induced damage due to the high oxygen demands of
the brain and low concentration of antioxidants, both
enzymatic (i.e. catalase, glutathione peroxidase, glutathione
reductase, superoxide dismutase) and non-enzymatic anti-
oxidants such as glutathione, vitamins A,C,D, coenzym Q,
uric acid etc. It is suggested that that antioxidant status was
altered and low activity of antioxidant enzymes were
observed in CNS of MS patients [5]. Enzymatic and non-
enzymatic antioxidants could regulate function of different
immunologic cells in MS. [5]. In addition, an impairment of
antioxidant defense systems in MS patients may results in
their higher susceptibility to ROS and cause damage of CNS
[7, 8]. The antioxidant enzymes such as superoxide dis-
mutase (SOD), catalase (CAT) and glutathione peroxidase
(GPx) are suggested to play a key role in pathogenesis of
MS by altered protection against ROS and/or RNS [18, 19].
Recently Choi et al. (2010) has been reported that GSH
levels measured in the fronto-parietal regions of the brain
were distinctly lower in SPMS patients [19]. Our previous
data also presented altered activity of antioxidant enzymes.
We found the decrease of SOD [7] and 2-fold higher
activity of CAT in erythrocytes of SPMS patients [8].
Moreover, the level of TAS in depressive MS was signiﬁ-
cantly lower than non-depressive MS as observed in our
study (P\0.0003) [20]. Finally, according to our previ-
ously published data we suggest that changes of non-
enzymatic antioxidants including glutathione (GSH), uric
acid, bilirubin, vitamins C, D and other exogenous antiox-
idants may be also responsible for a decrease of total anti-
oxidative status in MS patients [7, 8]. In current study we
selected only one subtype of MS patients with secondary
progressive clinical course. No signiﬁcant difference in
TAS between SPMS patients and controls was observed.
The determination of lipid peroxidation products relies
on different methods. The most widely used marker of lipid
peroxidation is the level of malonyldialdehyde (MDA) or
readily decomposed conjugated dienes in plasma or blood
cells. The commonly used assay for MDA based on the
reaction with thiobarbituric acid and formation of TBARS
is the most widely used method however, it is not sensitive
and non-speciﬁc since other metabolites can react with
thiobarbituric acid [21]. The data of our study presented
that lipid peroxidation estimated by TBARS generation in
SPMS patients comparing to healthy sex- and age-matched
controls were signiﬁcantly higher.
In order to eliminate these overestimation, we used a
sensitive immuneassay dedicated to isoprostanes which are
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Fig. 2 TBARS in plasma of secondary progressive multiple sclerosis
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Fig. 3 Total antioxidative status (TAS) in plasma of secondary
progressive multiple sclerosis (SPMS) patients and controls
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123proposed as the speciﬁc and reliable clinical marker of lipid
peroxidation. In our study isoprostanes were estimated in
urine of SPMS and healthy volunteers. Measurement of
8-epi-prostaglandin (PG)-F2a in a single sample of urine
represents daily secretion of isoprostanes, which are the
end products of peroxidation of arachnoidanate. Elevated
levels of 8-epi-prostaglandin (PG)-F2a have been previ-
ously described in neurological disorders such as Parkin-
son’s, Alzhaimer’s, Crotzfeld-Jacob disorders [11, 13].
Then, the elevated level of 8-epi-prostaglandin (PG)-F2a
reﬂects free radicals-induced lipid peroxidation and oxi-
dative stress. The source of 8-epi-prostaglandin (PG)-F2a
may be oxidized arachidonic acid derived not only from
neuron membranes but also from membrane of different
cells including erythrocytes [17].
The neuronal membranes contain a high amount of
polyunsturated fatty acid (in phospholipids) that can be the
potential site of oxidative stress. Oxidative damage of
neuronal membrane may lead to its altered structure and
dysfunction which may contribute to speciﬁc aspects of MS
symptomatology. The peroxidation of membrane lipids
changes ﬂuidity of membranes, their permeability and
exposition of receptors. It may lead to changes in signal
transduction and neurotransmission [6]. In diseases with a
complex pathogenesis, such as multiple sclerosis, an indi-
vidual biomarker is likely to reﬂect only one of many
ongoing pathogenic processes. The data presented in our
study indicate that lipid peroxidation and oxidative stress in
patients with MS may occur. Thus, we suggest that the
level of isoprostanes may be used as non-invasive marker
for a determination of oxidative stress in MS patients
which in turn may determine an speciﬁc antioxidative
therapy in SPMS patients. In progressive phase of MS
treatment with antioxidants and dietary supplements should
be taken into account.
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